Detail of Fig1E_SARS-CoV-2_2dpi_ibd-LoC



Project
Title
Fluorescence images of immunostaining analysis of SARS-CoV-2 NP in hepatocytes of bile duct (ibd-LoC) at 2 days post-infection (dpi).
Description
Fluorescence images of immunostaining analysis of SARS-CoV-2 NP in hepatocytes of bile duct (ibd-LoC) at 2 days post-infection (dpi).
Release, Updated
2023-07-20
License
CC BY
Kind
Image data
File Formats
.tif
Data size
926.1 KB

Organism
Homo sapiens ( NCBI:txid9606 )
Strain(s)
-
Cell Line
hepatocyte ( CLO_0000182 )

Datatype
-
Molecular Function (MF)
Biological Process (BP)
viral gene expression ( GO:0019080 ) cellular response to virus ( GO:0098586 )
Cellular Component (CC)
nucleus ( GO:0005634 )
Biological Imaging Method
fluorescence microscopy ( Fbbi:00000246 )
X scale
0.26458418 millimeter/pixel
Y scale
0.26458418 millimeter/pixel
Z scale
-
T scale
-

Image Acquisition
Experiment type
-
Microscope type
-
Acquisition mode
-
Contrast method
-
Microscope model
-
Detector model
-
Objective model
-
Filter set
-

Summary of Methods
See details in Deguchi S, et. al. (2023) PNAS Nexus, Mar 7;2(3):pgad029.
Related paper(s)

Sayaka Deguchi, Kaori Kosugi, Rina Hashimoto, Ayaka Sakamoto, Masaki Yamamoto, Rafal P Krol, Peter Gee, Ryosuke Negoro, Takeshi Noda, Takuya Yamamoto, Yu-Suke Torisawa, Miki Nagao, Kazuo Takayama (2023) Elucidation of the liver pathophysiology of COVID-19 patients using liver-on-a-chips., PNAS nexus, Volume 2, Number 3, pp. pgad029

Published in 2023 Mar (Electronic publication in March 7, 2023, midnight )

(Abstract) SARS-CoV-2 induces severe organ damage not only in the lung but also in the liver, heart, kidney, and intestine. It is known that COVID-19 severity correlates with liver dysfunction, but few studies have investigated the liver pathophysiology in COVID-19 patients. Here, we elucidated liver pathophysiology in COVID-19 patients using organs-on-a-chip technology and clinical analyses. First, we developed liver-on-a-chip (LoC) which recapitulating hepatic functions around the intrahepatic bile duct and blood vessel. We found that hepatic dysfunctions, but not hepatobiliary diseases, were strongly induced by SARS-CoV-2 infection. Next, we evaluated the therapeutic effects of COVID-19 drugs to inhibit viral replication and recover hepatic dysfunctions, and found that the combination of anti-viral and immunosuppressive drugs (Remdesivir and Baricitinib) is effective to treat hepatic dysfunctions caused by SARS-CoV-2 infection. Finally, we analyzed the sera obtained from COVID-19 patients, and revealed that COVID-19 patients, who were positive for serum viral RNA, are likely to become severe and develop hepatic dysfunctions, as compared with COVID-19 patients who were negative for serum viral RNA. We succeeded in modeling the liver pathophysiology of COVID-19 patients using LoC technology and clinical samples.

Contact
Kazuo Takayama , Kyoto University , Center for iPS Cell Research and Application (CiRA)
Contributors

OMERO Dataset
OMERO Project
Source